Диссертация (1139537), страница 47
Текст из файла (страница 47)
– 2016. – Vol. 21. – R066514.245. Esteve E. Dyslipidemia and inflammation: an evolutionary conserved mechanism/ E. Esteve, W. Ricart, J.M. Fernández-Real // Clin. Nutr. – 2005. – Vol. 24, № 1.– P. 16–31.246. Ethnic Differences in the Prevalence of Metabolic Syndrome: Results from a MultiEthnic Population-Based Survey in Malaysia [Resource electronic] / S.
Rampal [etal.]//PLoSOne.–2012.–Vol.7,№9.–URL:http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3460855/]247. European S3 – Guideline on the systemic treatment of psoriasis vulgaris – UpdatApremilast and Secukinumab – EDF in cooperation with EADV and IPC / A. Nast264[et al.] // J. Eur. Acad. Dermatol. Venereol. – 2017. – Vol. 31, № 12.
– P. 19511963.248. EUROPSO Patient Survey Group. European patient perspectives on the impact ofpsoriasis: the EUROPSO patient membership survey / L. Dubertret [et al.] // Br. J.Dermatol. – 2006. – Vol. 155, № 4. – P. 729–736.249. Evaluating the economic burden of psoriasis in the United States / J. VanderpuyeOrgle [et al.] // J. Am. Acad. Dermatol. – 2015.
– Vol. 72, № 6. – P. 961–967.250. Ferrante M. Effect of low–level laser therapy after extraction of impacted lowerthird molars / M. Ferrante, M. Petrini, P. Trentini // Lasers Med. Sci. – 2013. – Vol.28. – P. 845–849.251. Finlay A.Y. Quality of Life Survey / A.Y. Finlay // Exchange. – 1994. – P. 22-73.252. Ford E.S. Increasing Prevalence of the Metabolic Syndrome among U.S. / E.S.Ford, W.H. Giles, A.H.
Mokdad // Diabetes Care. – 2004. – Vol. 27. – P. 2444–2449.253. Ford E.S. Prevalence of the metabolic syndrome among US adults: findings fromthe third National Health and Nutrition Examination Survey / E.S. Ford, W.H. Gile,W.H. Dietz // JAMA. – 2002. – Vol. 287, № 3. – P.
356–359.254. Fredriksson T. Severe psoriasis – oral therapy with a new retinoid / T. Fredriksson,U. Pettersson // Dermatologica. – 1978. – Vol. 157, № 4. – P. 238–244.255. Frequency of streptococcal upper respiratory tract infections and HLA-Cw*06allele in 70 patients with guttate psoriasis from northern Poland / A. Maciejewska–Radomska [et al.] // Postepy Dermatol. Alergol.
– 2015. – Vol. 32, № 6. – P. 455–458.256. Fried R.G. Nonpharmacologic treatments in psychodermatology / R.G. Fried //Dermatol. Clin. – 2002. – Vol. 20, № 1. – P. 177–185.257. Garg N. Atherosclerosis in Psoriatic Arthritis: A Multiparametric Analysis UsingImaging Technique and Laboratory Markers of Inflammation and VascularFunction / N. Garg, P. Krishan, A. Syngle // Int. J. Angiol.
– 2016. – Vol. 25, № 4.– P. 222–228.265258. Garg T. Ancient and advanced approaches for the treatment of an inflammatoryautoimmune disease-psoriasis / T. Garg, G. Rath, A.K. Goyal // Crit. Rev. Ther.Drug Carrier Syst. – 2014. – Vol. 31, № 4. – P. 331–364.259. Genetic and epigenetic basis of psoriasis pathogenesis / A. Chandra [et al.] // Mol.Immunol. – 2015.
– Vo. 64, № 2. – P. 313–323.260. Genetic Epidemiology of Psoriasis / R. Gupta [et al.] // Curr. Dermatol. Rep. –2014. – Vol. 3, № 1. – P. 78.261. Genome-wide association analysis identifies three psoriasis susceptibility loci /P.E. Stuart [et al.] // Nat. Genet. – 2010. – Vol. 42. – P. 1000–1004.262. Gieler U. Hanterkranklingen in psychologischer / U. Gieler, U. Slangier, E.Brahler.
– Sicht-Gottingen, 1995. – 118 p.263. Gisondi P. Metabolic comorbidities and psoriasis / P. Gisondi, A. Ferrazzi, G.Girolomoni // Acta Dermatovenerol. Croat. – 2010. – Vol. 18. – P. 297–304.264. Golub M.S. The adrenal and the metabolic syndrome / M.S. Golub // Curr.Hypertens. Rep.
– 2001. – Vol. 3, № 2. – P. 117-120.265. Gooderham M. Apremilast in the treatment of psoriasis and psoriatic arthritis / M.Gooderham, K. Papp // Skin Therapy Lett. – 2015. – Vol. 20, № 5. – P. 1-6.266. Gordon K.B. Translating the Science of Psoriasis / K.B. Gordon // Semin. Cutan.Med. Surg. – 2016. – Vol. 35, № 4, Suppl. 4. – P. S64.267. Góth M.
Correlations between the hypothalamo-pituitary-adrenal axis and themetabolic syndrome / M. Góth, E. Hubina, M. Korbonits // Orv. Hetil. – 2005. –Vol. 146, № 2. – P. 51-55.268. Gottlieb A.B. A case of familial psoriasis with predominant hand involvement /A.B. Gottlieb, M.E. Weisfelner // J. Cutan. Med. Surg. – 2003. – Vol. 7, № 6.
– P.464–466.269. Griffiths C.E. Psychological influences in psoriasis / C.E. Griffiths, H.L. Richards// Clin. Exp. Dermatol. – 2001. – Vol. 26, № 4. – P. 338–342.270. Group for Research and Assessment of psoriasis and psoriatic arthritis 2015Treatment recommendations for psoriatic arthritis / L.C. Coates [et al.] // Arth.Rheumatol. – 2016. – Vol.
68. – P. 1060-1071.266271. Grundy S.M. Cardiovascular and metabolic risk factors: how can we improveoutcomes in the high–risk patient? / S.M. Grundy // Am. J. Med. – 2007. – № 120.– P. 3–8.272. Gupta M.A. Depression and suicidal ideation in dermatology patients with acne,alopecia areata, atopic dermatitis and psoriasis / M.A. Gupta, A.K. Gupta // Br.
J.Dermatol. – 1998. – Vol. 139, № 5. – P. 846–850.273. Gupta M.A. The Psoriasis Life Stress Inventory: a preliminary index of psoriasisrelated stress / M.A. Gupta, A.K. Gupta // Acta. Derm. Venereol. – 1995. – Vol.75, № 3. – P. 240–243.274. Hamblin M.R. Mechanisms of low level light therapy – an introduction / M.R.Hamblin, T.N. Demidova // Proc. SPIE. – 2006. – Vol. 61.
– P. 61001–61012.275. Harmonizing the metabolic syndrome: a joint interim statement of the InternationalDiabetes Federation Task Force on Epidemiology and Prevention / K.G. Alberti [etal.] // Circulation. – 2009. – Vol. 120, № 16. – P. 1640–1645.276. Heart disease and stroke statistics-2012 update: a report from the American HeartAssociation / V.L. Roger [et al.] // Circulation. – 2012. – Vol. 125. – Р.
2–220.277. Hébert H. Identification of loci associated with late–onset psoriasis using densegenotyping of immune-related regions / H. Hébert, J. Bowes, R. Smith // Brit. J. ofDermatology. – 2015. – Vol. 172, № 4. – P. 933–939.278. Heenen M. Psoriasis: pathogenesis and treatment / M. Heenen // Rev. Med. Brax.– 2003. – Vol. 24, № 3. – P. 139–147.279. Herschel T. Monoclonal antibodies, overview and outlook of a promisingtherapeutic option / T. Herschel, A. El-Armouche, S. Weber // Dtsch. Med.Wochenschr. – 2016. – Vol. 141, № 19.
– P. 1390–1394.280. High-sensitivity C-reactive protein in patients with metabolic syndrome / A. Guven[et al.] // Angiology. – 2006. – Vol. 57, № 3. – P. 295–302.281. Hotamisligil G.S. Adipose expression of tumor necrosis factor-α: direct role inobesity-linked insulin resistance / G.S. Hotamisligil, N.S. Shargill, B.M.Spiegelman // Science. – 1993. – Vol. 259. – P. 87–91.267282.
Human keratinocytes respond to interleukin-18: implication for the course ofchronic inflammatory skin diseases / M. Wittmann [et al.] // J. Invest. Dermatol. –2005. – Vol. 124, № 6. – P. 1225–1233.283. Hunecke P. Personlichkeitsstructur des Psoriatikers / P. Hunecke, K. Bosse //Zeitschr. Psychosom. Med. Psychoanal. – 1985. – № 30. – P.
105–118.284. IL-33 is regulated by TNF-α in normal and psoriatic skin / A. Balato [et al.] // Arch.Dermatol. Res. – 2014. – Vol. 306. – P. 299–304.285. Immunopathogenic mechanisms in psoriasis / J.E. Gudjonsson [et al.] // Clinical &Experimental Immunology. – 2004. – Vol. 135, № 1. – P. 1–8.286. In psoriatic lesional skin the type I interferon signaling pathway is activatedwhereas interferon-alpha sensitivity is unaltered / L. Van der Fits [et al.] // J. Invest.Dermatol.
– 2004. – Vol. 122, № 1. – P. 51–60.287. Inflammatory Markers Associated With Subclinical Coronary Artery Disease: TheMulticenter AIDS Cohort Study / H. Bahrami [et al.] // J. Am. Heart Assoc. – 2016.– Vol. 5, № 6. – e003371.288. Interleukin 17A: toward a new understanding of psoriasis pathogenesis / C.W.Lynde [et al.] // J. Am. Acad. Dermatol. – 2014. – Vol. 71, № 1. – P. 141–150.289. Interleukin-4, Oxidative Stress, Vascular Inflammation and Atherosclerosis / Y.W.Lee [et al.] // Biomol. Ther.
(Seoul). – 2010. – Vol. 18, № 2. – P. 135–144.290. Janke K. Hormonal and metabolic aspects of obesity in humans / K. Janke, H.Daweke, H. Liebermeister ; ed. J. Ostmann // Experta medica. – 1969. – P. 533–539.291. Karu T.I. Biomedical Photonics Handbook. Low-Power Laser Therapy / T.I. Karu.– CRC Press, 2003.
– 20 p.292. Kelley N.L. Living with psoriasis: a patient case study / N.L. Kelley // J. Vis.Commun Med. – 2015. – Vol. 38, № 3–4. – P. 164–167.293. Kokcami H. Antioxidants and lipid peroxidation status in the blood о patients withpsoriasis / H. Kokcami, M. Naziroglu // Clin. Chim. Acta. – 1999. – Vol. 289, №1–2. – P. 23–31.268294. Kontush A. Functionally defective high–density lipoprotein: a new therapeutictarget at the crossroads of dyslipidemia, inflammation, and atherosclerosis / A.Kontush, M.J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
